Navigation Links
deCODE Announces Positive Topline Results for Phase I Study of,DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ -- deCODE genetics today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi- dose, ascending dose, placebo-controlled clinical trial, a total of 40 healthy subjects were exposed to DG051 at doses up to 320mg per day for seven days. Building upon the positive results seen in the Phase I single dose study completed at the end of last year, key results were:

Safety and tolerability: DG051 was well tolerated at all dose levels tested, with no serious adverse events reported.

Dose-dependent reduction of leukotriene B4 (LTB4): DG051 was shown to reduce LTB4 production in a dose-dependent manner, with a peak reduction of more than 70% versus baseline after 7 days of treatment.

Pharmacokinetic profile: DG051 was found to have good bioavailability, with low variability between subjects. With a terminal half-life of approximately 9 hours and measurable concentrations at 24 hours after dosing, DG051 has a pharmacokinetic profile suitable for once-a-day dosing.

"The results of our Phase I trials show DG051 to be well tolerated and to provide a potent means of reining in the activity of the pathway our research has shown to modulate risk of heart attack. This latest study also provides us with pharmacodynamic data suggesting that we may be able to achieve a high steady-state reduction in LTB4 production with a dose in the middle of the range we have tested, and we look forward to entering DG051 into Phase II trials later this year," said Kari Stefansson, CEO of deCODE.

About DG051

DG051 is a first-in-class, small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H) discovered by deCODE's chemistry unit and being developed for the prevention of heart attack. LTA4H is encod
'"/>




Page: 1 2 3

Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/6/2015)... Inc. (Nasdaq: NXTM ), a leading manufacturer of ... that exceed the top end of its guidance range. ... 2015 increased 10 percent to $79.5 million, compared with ... 2014. The Company,s revenue guidance range for the first ... was driven by outperformance in the System One segment ...
(Date:5/6/2015)... Eli Lilly and Company (NYSE: LLY ... delivery and device innovation center in Cambridge, ... help attract top scientists and bioengineers, as well as ... The Lilly Cambridge Innovation Center, a makerspace located in ... organizations to explore how emerging technologies and connectivity can ...
(Date:5/6/2015)... 2015 According to a ... Market by Technology (Precipitation, Dialysis, Electrophoresis, Western Blotting, ... Kits, Reagents, Resins) by Application & End User ...  the global Protein Purification and Isolation Market was ... is expected to reach $ 6,370 Million by ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts 2Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts 3Protein Purification and Isolation Market Worth $6,370 Million by 2020 2Protein Purification and Isolation Market Worth $6,370 Million by 2020 3Protein Purification and Isolation Market Worth $6,370 Million by 2020 4
... LAKES, N.J. and MONTREAL, Oct. 13, 2011 A ... gene testing analysis found that 38 percent of patients ... clots, heart attack and stroke—were also using another drug ... http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) The analysis also showed that ...
... (NYSE AMEX: ULU ), announced today that it has ... company based in Switzerland, to license Altrazeal® for the European Union. ... the European Union rights to a subsidiary of Melmed Holdings AG ... for the license ULURU will receive a licensing payment and a ...
Cached Medicine Technology:Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 2Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 4ULURU Inc. Announces Altrazeal® Agreement for the European Market 2ULURU Inc. Announces Altrazeal® Agreement for the European Market 3
(Date:5/6/2015)... NY (PRWEB) May 06, 2015 ... design, creative and technology, announced today that its founder ... advisor by Shocase, a marketing professional network aimed at ... sector. , Widely regarded as a specialist in the ... most high-profile branding programs over the last three decades, ...
(Date:5/6/2015)... Mesa, Arizona (PRWEB) May 6, ... Ventures, Inc. (MAV), an investor backed Colorado cannabis ... based Phoenician Engineering subsidiary three times since first ... achieved profitability from operations, within one year of ... the end of 2014 to over 500 today ...
(Date:5/6/2015)... celebration of their twentieth anniversary, Premierlacewigs.com launched a ... a deluxe human hair lace wig valued at $300 USD ... a third-party giveaway tool. The important thing is the winner ... , The hair is a crown, a reflection of inner ... jewel for the past 20 years. Whether it is for ...
(Date:5/6/2015)... Hope For The Warriors® and American Legion Post ... New York Athletic Club on April 21, 2015. All ... a national nonprofit dedicated to restoring a sense of ... our service members and our military families. , Casino ... nationwide military families. The Barry Fixler Foundation/Semper Cool (fixlerfoundation.org) ...
(Date:5/6/2015)... May 06, 2015 Most people in the ... nursing or other care after age 65. But less than ... for it or even talking about it, reports the May ... people risk two problems. One is losing control over the ... families," says Dr. David Grabowski, a professor of health care ...
Breaking Medicine News(10 mins):Health News:Shocase Selects MBLM’s Claude Salzberger as Company Advisor 2Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2Health News:PremierLaceWigs.com Human Hair Lace Wigs Giveaway Could Change Your Hairstyle 2Health News:4th Annual Casino Night Draws Support for Military Families in New York City Region 2Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2
... 2, 2009) New research published in the February issue ... shows a warm-up of 15 to 20 minutes with ... substantial increase in proficiency of surgical skills in surgeons of ... both psychomotor and cognitive skills raises surgeons, alertness to a ...
... (NYSE: WTW ) will release its results for ... close on Wednesday, March 4, 2009.The Company has also scheduled ... During the conference call, David Kirchhoff, President and Chief Executive ... quarter and full year results and answer questions from the ...
... /PRNewswire/ -- Kirby Lester, LLC, the world,s ... automated technology breakthrough: the KL30 automated dispensing and ... sized and priced for any retail pharmacy or hospital ... per day.Kirby Lester introduced the KL30 today at the ...
... CHICAGO, Feb. 2 The American Dietetic Association will pursue ... and recommend to Congress that a primary goal of new ... of our citizens should improve as a result of our ... M. Yadrick. "Nutrition needs to rise as a national priority, ...
... Meet in Boise, Idaho, Feb. 7-13 to Promote Acceptance ... World ATLANTA, Feb. 2 Wesley Mosley from ... from around the world to participate in the fifth ... be held in conjunction with the 2009 Special Olympics ...
... CarePHOENIX, Feb. 2 In celebration of American ... Annual Public Forum showcasing a live- telecast ... blood vessel disease on Tuesday, February 10, 2009. ... Founder and Medical Director of Arizona Heart Institute ...
Cached Medicine News:Health News:Journal of American College of Surgeons study finds warm-up helps surgeons improve performance 2Health News:Weight Watchers Announces Fourth Quarter and Full Year 2008 Earnings Conference Call 2Health News:Kirby Lester's New KL30: Fully Automated, Compact System for a Fraction of the Cost of a Robotic Dispenser 2Health News:Kirby Lester's New KL30: Fully Automated, Compact System for a Fraction of the Cost of a Robotic Dispenser 3Health News:American Dietetic Association Announces Agenda for Health Reform 2Health News:Wesley Mosley Selected to Participate in Global Youth Activation Summit During the 2009 Special Olympics World Winter Games 2Health News:Wesley Mosley Selected to Participate in Global Youth Activation Summit During the 2009 Special Olympics World Winter Games 3Health News:Arizona Heart Institute Announces FREE Public Forum Featuring Live Viewing of Surgical Procedures Via High-Definition (HD) Satellite 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: